ALT
Altimmune, Inc.
Price Chart
Latest Quote
$2.87
+0.02 (+0.70%)
Current Price
| Previous Close | $2.85 |
| Open | $2.78 |
| Day High | $2.95 |
| Day Low | $2.77 |
| Volume | 2,962,450 |
Stock Information
| Shares Outstanding | 194.47M |
| Total Debt | $35.85M |
| Cash Equivalents | $331.54M |
| Revenue | $36K |
| Net Income | $-91.08M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $558.14M |
| EPS (TTM) | $-0.92 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $262.45M |
| Sales | $36K |
| Income | $-91.08M |
| Book/sh | $2.18 |
| Cash/sh | $1.70 |
| Employees | 57 |
Financial Ratios
| Quick Ratio | 29.43 |
| Current Ratio | 29.56 |
| Debt/Eq | 12.62 |
Returns & Margins
| ROA | -24.40% |
| ROE | -42.75% |
| Operating Margin | -267247.22% |
Ownership
| Insider Ownership | 0.41% |
| Institutional Ownership | 58.08% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.34 |
| PEG | 32.62 |
| P/S | 15503.91 |
| P/B | 1.32 |
Analyst Data
| Recommendation | buy |
| Target Price | $15.45 |
Technical Indicators
| SMA20 | $2.97 |
| SMA50 | $2.91 |
| SMA200 | $3.82 |
| RSI | 52.58 |
| ATR | 0.1785 |
| Shares Float | 164.20M |
| Short Float | 24.52% |
| Short Ratio | 10.92 |
| Volatility | 0.24 |
| Rel Volume | 0.60 |
Performance History
| Week | -5.90% |
| Month | +9.54% |
| Quarter | -18.23% |
| 6 Months | -31.34% |
| YTD | -18.23% |
| Year | -31.34% |
| 3 Years | -13.55% |
| 5 Years | -68.84% |
| 10 Years | -97.85% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $2.87 | 2,963,300 |
| 2026-07-16 | $2.85 | 2,995,400 |
| 2026-07-15 | $2.98 | 2,862,400 |
| 2026-07-14 | $2.93 | 3,299,000 |
| 2026-07-13 | $2.99 | 2,457,100 |
| 2026-07-10 | $3.05 | 2,992,900 |
| 2026-07-09 | $3.12 | 2,877,000 |
| 2026-07-08 | $3.11 | 3,520,300 |
| 2026-07-07 | $3.02 | 4,619,800 |
| 2026-07-06 | $3.08 | 4,348,100 |
| 2026-07-02 | $3.16 | 4,055,500 |
| 2026-07-01 | $3.15 | 7,976,000 |
| 2026-06-30 | $3.04 | 4,332,500 |
| 2026-06-29 | $2.94 | 3,638,900 |
| 2026-06-26 | $2.82 | 17,105,400 |
| 2026-06-25 | $2.87 | 2,781,400 |
| 2026-06-24 | $2.95 | 3,494,100 |
| 2026-06-23 | $2.91 | 4,223,900 |
| 2026-06-22 | $2.93 | 5,776,500 |
| 2026-06-18 | $2.70 | 11,688,200 |
About Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
đ° Latest News
US Research house initiates Solvonis coverage citing differentiated addiction strategy
Proactive âĸ 2026-07-13T09:10:00Z
Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market
Insider Monkey âĸ 2026-07-05T22:08:31Z
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Zacks âĸ 2026-06-26T08:59:00Z
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Zacks âĸ 2026-06-25T12:40:00Z
Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?
Insider Monkey âĸ 2026-06-24T13:26:22Z
Why Altimmune (ALT) Could Strengthen Its MASH Case With Pemvidutideâs Broader Metabolic Data
Insider Monkey âĸ 2026-06-17T15:16:22Z
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
Zacks âĸ 2026-06-12T15:30:02Z
Altimmune Sets Pemvidutideâs Phase 3 MASH Playbook as AUD Data Near
MarketBeat âĸ 2026-06-10T13:05:14Z
ALT and the Rise of Dual Agonists Targeting Liver Disease
Zacks âĸ 2026-06-08T16:09:00Z
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
Zacks âĸ 2026-06-08T16:06:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $41,000 | $20,000 | $426,000 | $-68,000 |
| Operating Revenue | $41,000 | $20,000 | $426,000 | $-68,000 |
| Expenses | ||||
| Interest Expense | $1,636,000 | $9,000 | $35,000 | $8,000 |
| Total Expenses | $94,530,000 | $103,192,000 | $83,936,000 | $87,672,000 |
| Other Income Expense | $-190,000 | $48,000 | $-12,253,000 | $-32,000 |
| Other Non Operating Income Expenses | $-190,000 | $48,000 | $166,000 | $-32,000 |
| Net Non Operating Interest Income Expense | $5,905,000 | $8,065,000 | $7,316,000 | $2,862,000 |
| Interest Expense Non Operating | $1,636,000 | $9,000 | $35,000 | $8,000 |
| Operating Expense | $94,530,000 | $103,192,000 | $83,936,000 | $87,672,000 |
| General And Administrative Expense | $28,098,000 | $20,966,000 | $18,137,000 | $17,134,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-88,093,000 | $-95,059,000 | $-88,447,000 | $-84,713,000 |
| Net Interest Income | $5,905,000 | $8,065,000 | $7,316,000 | $2,862,000 |
| Interest Income | $7,541,000 | $8,074,000 | $7,351,000 | $2,870,000 |
| Normalized Income | $-88,093,000 | $-95,059,000 | $-76,028,000 | $-84,713,000 |
| Net Income From Continuing And Discontinued Operation | $-88,093,000 | $-95,059,000 | $-88,447,000 | $-84,713,000 |
| Total Operating Income As Reported | $-94,489,000 | $-103,172,000 | $-95,929,000 | $-87,740,000 |
| Net Income Common Stockholders | $-88,093,000 | $-95,059,000 | $-88,447,000 | $-84,713,000 |
| Net Income | $-88,093,000 | $-95,059,000 | $-88,447,000 | $-84,713,000 |
| Net Income Including Noncontrolling Interests | $-88,093,000 | $-95,059,000 | $-88,447,000 | $-84,713,000 |
| Net Income Continuous Operations | $-88,093,000 | $-95,059,000 | $-88,447,000 | $-84,713,000 |
| Pretax Income | $-88,774,000 | $-95,059,000 | $-88,447,000 | $-84,910,000 |
| Interest Income Non Operating | $7,541,000 | $8,074,000 | $7,351,000 | $2,870,000 |
| Operating Income | $-94,489,000 | $-103,172,000 | $-83,510,000 | $-87,740,000 |
| Special Income Charges | - | $0 | $-12,419,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-1.00 | $-1.34 | $-1.66 | $-1.81 |
| Basic EPS | $-1.00 | $-1.34 | $-1.66 | $-1.81 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-87,026,000 | $-94,812,000 | $-75,516,000 | $-84,409,000 |
| Reconciled Depreciation | $112,000 | $238,000 | $477,000 | $493,000 |
| EBITDA (Bullshit earnings) | $-87,026,000 | $-94,812,000 | $-87,935,000 | $-84,409,000 |
| EBIT | $-87,138,000 | $-95,050,000 | $-88,412,000 | $-84,902,000 |
| Diluted Average Shares | $88,104,132 | $71,003,399 | $53,246,937 | $46,926,349 |
| Basic Average Shares | $88,104,132 | $71,003,399 | $53,246,937 | $46,926,349 |
| Diluted NI Availto Com Stockholders | $-88,093,000 | $-95,059,000 | $-88,447,000 | $-84,713,000 |
| Tax Provision | $-681,000 | $0 | $0 | $-197,000 |
| Research And Development | $66,432,000 | $82,226,000 | $65,799,000 | $70,538,000 |
| Selling General And Administration | $28,098,000 | $20,966,000 | $18,137,000 | $17,134,000 |
| Other Gand A | $28,098,000 | $20,966,000 | $18,137,000 | $17,134,000 |
| Total Unusual Items | - | $0 | $-12,419,000 | $0 |
| Total Unusual Items Excluding Goodwill | - | $0 | $-12,419,000 | $0 |
| Impairment Of Capital Assets | - | $0 | $12,419,000 | $0 |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $224,892,000 | $123,508,000 | $194,099,000 | $172,874,000 |
| Total Assets | $279,929,000 | $139,306,000 | $210,640,000 | $206,928,000 |
| Total Non Current Assets | $1,737,000 | $2,052,000 | $1,014,000 | $14,115,000 |
| Other Non Current Assets | $1,425,000 | $1,639,000 | $363,000 | $615,000 |
| Current Assets | $278,192,000 | $137,254,000 | $209,626,000 | $192,813,000 |
| Other Current Assets | $2,957,000 | $2,204,000 | $6,917,000 | $5,358,000 |
| Restricted Cash | $42,000 | $42,000 | $41,000 | $34,000 |
| Receivables | $1,737,000 | $3,117,000 | $4,853,000 | $2,541,000 |
| Taxes Receivable | $518,000 | $2,573,000 | $3,742,000 | $2,368,000 |
| Accounts Receivable | $1,219,000 | $544,000 | $1,111,000 | $173,000 |
| Cash Cash Equivalents And Short Term Investments | $273,456,000 | $131,891,000 | $197,815,000 | $184,880,000 |
| Cash And Cash Equivalents | $43,760,000 | $36,926,000 | $135,117,000 | $111,097,000 |
| Goodwill And Other Intangible Assets | - | - | $0 | $12,419,000 |
| Other Intangible Assets | - | - | - | $12,419,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $35,688,000 | $1,681,000 | $671,000 | $1,124,000 |
| Long Term Debt And Capital Lease Obligation | $35,432,000 | $1,402,000 | $175,000 | $672,000 |
| Long Term Debt | $34,287,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $256,000 | $279,000 | $496,000 | $452,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $55,037,000 | $15,798,000 | $16,541,000 | $21,635,000 |
| Total Non Current Liabilities Net Minority Interest | $40,040,000 | $5,330,000 | $4,398,000 | $4,581,000 |
| Other Non Current Liabilities | $4,448,000 | $3,768,000 | $4,223,000 | $3,909,000 |
| Non Current Deferred Liabilities | $160,000 | $160,000 | - | - |
| Current Liabilities | $14,997,000 | $10,468,000 | $12,143,000 | $17,054,000 |
| Payables And Accrued Expenses | $14,741,000 | $10,189,000 | $11,647,000 | $16,602,000 |
| Interest Payable | $315,000 | $55,000 | $124,000 | $103,000 |
| Payables | $2,717,000 | $211,000 | $2,070,000 | $5,973,000 |
| Accounts Payable | $2,717,000 | $211,000 | $2,070,000 | $4,804,000 |
| Total Tax Payable | - | - | $0 | $1,169,000 |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $224,892,000 | $123,508,000 | $194,099,000 | $185,293,000 |
| Total Equity Gross Minority Interest | $224,892,000 | $123,508,000 | $194,099,000 | $185,293,000 |
| Stockholders Equity | $224,892,000 | $123,508,000 | $194,099,000 | $185,293,000 |
| Gains Losses Not Affecting Retained Earnings | $-4,928,000 | $-4,973,000 | $-5,004,000 | $-5,227,000 |
| Other Equity Adjustments | $-4,928,000 | $-4,973,000 | $-5,004,000 | $-5,227,000 |
| Retained Earnings | $-649,483,000 | $-561,390,000 | $-466,331,000 | $-377,884,000 |
| Other | ||||
| Ordinary Shares Number | $110,882,735 | $72,352,701 | $70,677,400 | $49,199,845 |
| Share Issued | $110,882,735 | $72,352,701 | $70,677,400 | $49,199,845 |
| Tangible Book Value | $224,892,000 | $123,508,000 | $194,099,000 | $172,874,000 |
| Invested Capital | $259,179,000 | $123,508,000 | $194,099,000 | $185,293,000 |
| Working Capital | $263,195,000 | $126,786,000 | $197,483,000 | $175,759,000 |
| Capital Lease Obligations | $1,401,000 | $1,681,000 | $671,000 | $1,124,000 |
| Total Capitalization | $259,179,000 | $123,508,000 | $194,099,000 | $185,293,000 |
| Additional Paid In Capital | $879,292,000 | $689,864,000 | $665,427,000 | $568,399,000 |
| Capital Stock | $11,000 | $7,000 | $7,000 | $5,000 |
| Common Stock | $11,000 | $7,000 | $7,000 | $5,000 |
| Non Current Deferred Revenue | $160,000 | $160,000 | - | - |
| Long Term Capital Lease Obligation | $1,145,000 | $1,402,000 | $175,000 | $672,000 |
| Current Capital Lease Obligation | $256,000 | $279,000 | $496,000 | $452,000 |
| Current Accrued Expenses | $12,024,000 | $9,978,000 | $9,577,000 | $10,629,000 |
| Net PPE | $312,000 | $413,000 | $651,000 | $1,081,000 |
| Accumulated Depreciation | $-2,325,000 | $-2,213,000 | $-1,975,000 | $-1,498,000 |
| Gross PPE | $2,637,000 | $2,626,000 | $2,626,000 | $2,579,000 |
| Leases | $1,749,000 | $1,749,000 | $1,749,000 | $1,749,000 |
| Other Properties | $342,000 | $342,000 | $342,000 | $295,000 |
| Machinery Furniture Equipment | $546,000 | $535,000 | $535,000 | $535,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $229,696,000 | $94,965,000 | $62,698,000 | $73,783,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-67,546,000 | $-79,848,000 | $-75,857,000 | $-62,712,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-67,535,000 | $-79,848,000 | $-75,810,000 | $-62,586,000 |
| Cash Flow From Continuing Operating Activities | $-67,535,000 | $-79,848,000 | $-75,810,000 | $-62,586,000 |
| Operating Gains Losses | $160,000 | $-48,000 | $-154,000 | $34,000 |
| Investing Activities | ||||
| Capital Expenditure | $-11,000 | - | $-47,000 | $-126,000 |
| Investing Cash Flow | $-132,473,000 | $-28,386,000 | $13,732,000 | $-73,399,000 |
| Cash Flow From Continuing Investing Activities | $-132,473,000 | $-28,386,000 | $13,732,000 | $-73,399,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $173,733,000 | $9,994,000 | $86,601,000 | $56,347,000 |
| Financing Cash Flow | $206,842,000 | $10,044,000 | $86,105,000 | $56,781,000 |
| Cash Flow From Continuing Financing Activities | $206,842,000 | $10,044,000 | $86,105,000 | $56,781,000 |
| Net Other Financing Charges | $-2,223,000 | $-850,000 | $-824,000 | $-516,000 |
| Net Common Stock Issuance | $173,733,000 | $9,994,000 | $86,601,000 | $56,347,000 |
| Common Stock Issuance | $173,733,000 | $9,994,000 | $86,601,000 | $56,347,000 |
| Other | ||||
| Issuance Of Debt | $35,000,000 | $0 | - | - |
| Interest Paid Supplemental Data | $975,000 | $0 | - | - |
| End Cash Position | $43,802,000 | $36,968,000 | $135,158,000 | $111,131,000 |
| Beginning Cash Position | $36,968,000 | $135,158,000 | $111,131,000 | $190,335,000 |
| Changes In Cash | $6,834,000 | $-98,190,000 | $24,027,000 | $-79,204,000 |
| Proceeds From Stock Option Exercised | $332,000 | $900,000 | $328,000 | $950,000 |
| Net Issuance Payments Of Debt | $35,000,000 | $0 | - | - |
| Net Long Term Debt Issuance | $35,000,000 | $0 | - | - |
| Long Term Debt Issuance | $35,000,000 | $0 | - | - |
| Net Investment Purchase And Sale | $-132,462,000 | $-28,386,000 | $13,779,000 | $-73,273,000 |
| Sale Of Investment | $152,986,000 | $87,345,000 | $102,410,000 | $0 |
| Purchase Of Investment | $-285,448,000 | $-115,731,000 | $-88,631,000 | $-73,273,000 |
| Net PPE Purchase And Sale | $-11,000 | $0 | $-47,000 | $-126,000 |
| Purchase Of PPE | $-11,000 | $0 | $-47,000 | $-126,000 |
| Change In Working Capital | $6,752,000 | $4,478,000 | $-8,274,000 | $14,111,000 |
| Change In Payables And Accrued Expense | $4,895,000 | $-1,971,000 | $-4,617,000 | $8,163,000 |
| Change In Accrued Expense | $2,389,000 | $-112,000 | $-1,883,000 | $5,393,000 |
| Change In Payable | $2,506,000 | $-1,859,000 | $-2,734,000 | $2,770,000 |
| Change In Account Payable | $2,506,000 | $-1,859,000 | $-2,734,000 | $2,770,000 |
| Change In Prepaid Assets | $-204,000 | $4,713,000 | $-1,345,000 | $2,650,000 |
| Change In Receivables | $2,061,000 | $1,736,000 | $-2,312,000 | $3,298,000 |
| Changes In Account Receivables | $-675,000 | $567,000 | $-938,000 | $256,000 |
| Other Non Cash Items | $363,000 | - | - | $86,000 |
| Stock Based Compensation | $16,076,000 | $14,393,000 | $10,640,000 | $8,101,000 |
| Amortization Of Securities | $-2,224,000 | $-3,850,000 | $-2,471,000 | $-698,000 |
| Deferred Tax | $-681,000 | $0 | - | - |
| Deferred Income Tax | $-681,000 | $0 | - | - |
| Depreciation Amortization Depletion | $112,000 | $238,000 | $477,000 | $493,000 |
| Depreciation And Amortization | $112,000 | $238,000 | $477,000 | $493,000 |
| Depreciation | $112,000 | $238,000 | $477,000 | $493,000 |
| Net Foreign Currency Exchange Gain Loss | $160,000 | $-48,000 | $-154,000 | $34,000 |
| Net Income From Continuing Operations | $-88,093,000 | $-95,059,000 | $-88,447,000 | $-84,713,000 |
| Asset Impairment Charge | - | $0 | $12,419,000 | $0 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
| Repayment Of Debt | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
Fetched: 2026-07-15